Catalyst Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Catalyst Pharmaceuticals has been growing earnings at an average annual rate of 35.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 39.4% per year. Catalyst Pharmaceuticals's return on equity is 18.4%, and it has net margins of 17.9%.
Key information
35.5%
Earnings growth rate
35.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 39.4% |
| Return on equity | 18.4% |
| Net Margin | 17.9% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Catalyst Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 398 | 71 | 134 | 0 |
| 30 Sep 23 | 348 | 62 | 107 | 0 |
| 30 Jun 23 | 303 | 116 | 87 | 0 |
| 31 Mar 23 | 256 | 99 | 71 | 0 |
| 31 Dec 22 | 214 | 83 | 57 | 0 |
| 30 Sep 22 | 192 | 67 | 56 | 0 |
| 30 Jun 22 | 170 | 54 | 55 | 0 |
| 31 Mar 22 | 154 | 45 | 53 | 0 |
| 31 Dec 21 | 141 | 39 | 50 | 0 |
| 30 Sep 21 | 134 | 42 | 50 | 0 |
| 30 Jun 21 | 127 | 75 | 48 | 0 |
| 31 Mar 21 | 120 | 72 | 47 | 0 |
| 31 Dec 20 | 119 | 75 | 44 | 0 |
| 30 Sep 20 | 118 | 71 | 42 | 0 |
| 30 Jun 20 | 120 | 42 | 40 | 0 |
| 31 Mar 20 | 119 | 43 | 39 | 0 |
| 31 Dec 19 | 102 | 32 | 37 | 0 |
| 30 Sep 19 | 73 | 9 | 32 | 0 |
| 30 Jun 19 | 42 | -12 | 28 | 0 |
| 31 Mar 19 | 13 | -29 | 22 | 0 |
| 31 Dec 18 | 1 | -34 | 16 | 0 |
| 30 Sep 18 | 0 | -25 | 11 | 0 |
| 30 Jun 18 | 0 | -21 | 9 | 0 |
| 31 Mar 18 | 0 | -19 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 7 | 0 |
| 30 Sep 17 | 0 | -17 | 6 | 0 |
| 30 Jun 17 | 0 | -17 | 6 | 0 |
| 31 Mar 17 | 0 | -18 | 6 | -4 |
| 31 Dec 16 | 0 | -18 | 7 | 0 |
| 30 Sep 16 | 0 | -20 | 9 | 4 |
| 30 Jun 16 | 0 | -20 | 9 | 7 |
| 31 Mar 16 | 0 | -20 | 9 | 13 |
| 31 Dec 15 | 0 | -20 | 9 | 0 |
| 30 Sep 15 | 0 | -18 | 8 | 10 |
| 30 Jun 15 | 0 | -18 | 7 | 10 |
| 31 Mar 15 | 0 | -17 | 6 | 10 |
| 31 Dec 14 | 0 | -16 | 4 | 10 |
| 30 Sep 14 | 0 | -13 | 4 | 10 |
| 30 Jun 14 | 0 | -14 | 3 | 10 |
| 31 Mar 14 | 0 | -14 | 2 | 10 |
| 31 Dec 13 | 0 | -12 | 2 | 8 |
| 30 Sep 13 | 0 | -11 | 2 | 7 |
Quality Earnings: CN2 has a high level of non-cash earnings.
Growing Profit Margin: CN2's current net profit margins (17.9%) are lower than last year (38.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CN2 has become profitable over the past 5 years, growing earnings by 35.5% per year.
Accelerating Growth: CN2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CN2 had negative earnings growth (-14%) over the past year, making it difficult to compare to the Biotechs industry average (-11.5%).
Return on Equity
High ROE: CN2's Return on Equity (18.4%) is considered low.